Adverse skin reactions during treatment with cetuximab plus radiotherapy: Multidisciplinary approach to minimize radio-chemotherapy interruption

References

• Jost M, Kari C, Rodeck U. The EGF receptor-an essential regulator of multiple epidermal functions. Eur J Dermatol. 2000;10:505–10
   PubMed Web of Science ®Google Scholar
• Harari PM, Huang SM. Head and neck cancer as a clinical model for molecular targeting therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys. 2001;49:427–33
   PubMed Web of Science ®Google Scholar
• Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:2311–19
   PubMed Web of Science ®Google Scholar
• Pirker R, Pereira JR, Von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 2012;13:33–42
   PubMed Web of Science ®Google Scholar
• Thomas M. Cetuximab: adverse event profile and recommendations for toxicity management. Clin J Oncol Nurs. 2005;9:332–8
   PubMedGoogle Scholar
• Baas JM, Krens LL, Guchelaar HJ, et al. Recommendations on management of EGFR inhibitor-induced skin toxicity: a systematic review. Cancer Treat Rev. 2012;38:505–14
   PubMed Web of Science ®Google Scholar
• Ocvirk J, Cencelj S. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer. J Eur Acad Dermatol Venereol. 2010;24:453–9
   PubMed Web of Science ®Google Scholar
• Pinto C, Barone CA, Girolomoni G, et al. Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist. 2011;16:228–38
   PubMed Web of Science ®Google Scholar
• Bernier J, Bonner J, Vermorken JB, et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol. 2008;19:142–9
   PubMed Web of Science ®Google Scholar
• Fleming ID, Cooper J, Henson D, eds. AJCC Cancer Staging Manual, 5th ed. Philadelphia: Lippincott-Raven, 1998
   Google Scholar
• Common Terminology Criteria for Adverse Events v4.0 (CTCAE). Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev4.pdf
   Google Scholar
• Jensen AN, Nelleman HM, Overgaard J. Tumor progression in waiting time for radiotherapy in head and neck cancer. Radioth Oncol. 2007;84:5–10
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003;21:2787–99
   PubMed Web of Science ®Google Scholar
• Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341–54
   PubMed Web of Science ®Google Scholar
• Jost M, Kari C, Rodeck U. The EGF receptor-An essential regulator of multiple epidermal functions. Eur J Dermatol. 2000;10:505–10
   PubMed Web of Science ®Google Scholar
• Kalyankrishina S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol. 2006;24:2666–72
   Google Scholar
• Robert E, Ezekiel MP, Spencer SA, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol. 2001;19:3234–43
   PubMed Web of Science ®Google Scholar
• Ang KK, Andratschke NH, Milas L. Epidermal growth factor receptor and response of head and neck carcinoma to therapy. Int J Radiat Oncol Biol Phys. 2004;58:959–65
   PubMed Web of Science ®Google Scholar
• Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62:7350–6
   PubMed Web of Science ®Google Scholar
• Budach W, Bölke E, Homey B. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med. 2007;357:514–15
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–78
   PubMed Web of Science ®Google Scholar
• Berger B, Belka C. Severe skin reaction secondary to concomitant radiotherapy plus cetuximab. Radiat Oncol. 2008;3:5. doi: 10.1186/1748-717X-3-5
   PubMed Web of Science ®Google Scholar
• Mydin AR, Armstrong JG. Acneiform rash secondary to cetuximab plus head and neck radiotherapy. Radiother Oncol. 2007;85:171
   PubMedGoogle Scholar
• Bölke E, Gerber PA, Lammering G, et al. Development and management of severe cutaneous side effects in head and neck cancer patients during concurrent radiotherapy and cetuximab. Strahlenther Onkol. 2008;184:105–10
   PubMedGoogle Scholar
• Cotena C, Gisondi P, Colato C, Girolomoni G. Acneiform eruption induced by cetuximab. Acta Dermatovenereol Croat. 2007;15:246–8
   Google Scholar
• Gencoglan G, Ceylan C. Two cases of acneiform eruption induced by inhibitor of epidermal growth factor receptor. Skin Pharmacol Physiol. 2007;20:260–2
   Google Scholar
• Jacot W, Bessis D, Jorda E, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dematol. 2004;151:238–41
   PubMed Web of Science ®Google Scholar
• Guerriero C, Ricci F, Paradisi A, et al. Subcutaneous abscess as a side-effect of cetuximab therapy. Eur J Dermatol. 2011;21:277–8
   Google Scholar
• Ricci F, Guerriero C, Paradisi A, et al. Multiple abscesses in a patient treated with cetuximab. Eur J Dermatol. 2013;23:103–4
   Google Scholar
• Lacouture ME. Mechanism of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006;6:803–12
   PubMed Web of Science ®Google Scholar
• Hu JC, Sadeghi P, Pinter-Brown LC, et al. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis and management. J Am Acad Dermatol. 2007;56:317–26
   PubMed Web of Science ®Google Scholar
• Eilers RE Jr, Gandhi M, Patel JD, et al. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst. 2010;102:47–53
   PubMedGoogle Scholar
• Hymes SR, Stro E, Fife C. Radiation dermatitis: clinical presentation. Pathophysiology and treatment. J Am Acad Dermatol. 2006;54:28–46
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11:21–8
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–27
   PubMed Web of Science ®Google Scholar
• Peeters M, Siena S, Van Cutsem E, et al. Association of progression-free survival, overall survival, and patients-reported outcomes by skin toxicity and Kras status in patients receiving panitumumab monotherapy. Cancer. 2009;115:1544–54
   PubMed Web of Science ®Google Scholar
• Orditura M, De Vita F, Galizia G, et al. Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis. Oncol Rep. 2009;21:1023–8
   PubMed Web of Science ®Google Scholar
• Duffour J, Thézenas S, Dereure O, et al. Inter-observer agreement between dermatologists and oncologists in assessing dermatological toxicities in patients with metastatic colorectal cancer treated by cetuximab-based chemotherapies: a pilot comparative study. Eur J Cancer. 2010;46:3169–74
   PubMed Web of Science ®Google Scholar